Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSIT-1: Transition from Inhaled Treprostinil to Oral Selexipag in PAH
NCT02471183Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Oct 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Percentage of Subjects With Sustained Treatment Transition at 16 weeks, Percentage of Subjects With Treatment-emergent Adverse Events at 26 weeks and 5 more. Started Oct 2015; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02471183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471183.